ART-TG, Inserm, Corbeil-Essonnes, France.
Department of Medical Microbiology Laboratory of Experimental Virology Amsterdam UMC, AMC, University of Amsterdam, Amsterdam, the Netherlands.
Hum Gene Ther. 2023 Sep;34(17-18):896-904. doi: 10.1089/hum.2023.123.
The development of prophylatic or therapeutic medicines for infectious diseases is one of the priorities for health organizations worldwide. Innovative solutions are required to achieve effective, safe, and accessible treatments for most if not all infectious diseases, particularly those that are chronic in nature or that emerge unexpectedly over time. Genetic technologies offer versatile possibilities to design therapies against pathogens. Recent developments such as mRNA vaccines, CRISPR gene editing, and immunotherapies provide unprecedented hope to achieve significant results in the field of infectious diseases. This review will focus on advances in this domain, showcasing the cross-fertilization with other fields ( oncology), and addressing some of the logistical and economic concerns important to consider when making these advances accessible to diverse populations around the world.
为传染病开发预防或治疗药物是全球卫生组织的优先事项之一。需要创新的解决方案,以实现针对大多数(如果不是全部)传染病的有效、安全和可及的治疗方法,特别是那些具有慢性性质或随着时间的推移而意外出现的传染病。遗传技术为针对病原体设计疗法提供了多种可能性。最近的发展,如 mRNA 疫苗、CRISPR 基因编辑和免疫疗法,为传染病领域取得重大成果提供了前所未有的希望。这篇综述将重点介绍该领域的进展,展示与其他领域(肿瘤学)的交叉融合,并解决在使这些进展为世界各地的不同人群所接受时需要考虑的一些后勤和经济方面的问题。